Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals
Autor: | Guillaume Martin-Blondel, Jacques Izopet, Mary Requena, Bertrand Suc, Laurent Alric, Manon Nayrac, Nicolas Carrere, Pierre Delobel, Karl Barange, Claire Loiseau, Michelle Cazabat |
---|---|
Přispěvatelé: | Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), James Cook University (JCU), Chirurgie Générale et Digestive [Rangueil], Université de Toulouse (UT), Pôle Maladies de l'appareil digestif [CHU Toulouse], Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], CHU Toulouse [Toulouse]-Hôpital de Rangueil, Université Fédérale Toulouse Midi-Pyrénées, Service de Gastro-entérologie - Hépatologie [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), Service des maladies infectieuses et tropicales [Toulouse], Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Chemokine [SDV]Life Sciences [q-bio] HIV Infections C-C chemokine receptor type 6 MESH: Antiretroviral Therapy Highly Active 0302 clinical medicine T-Lymphocyte Subsets [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Antiretroviral Therapy Highly Active MESH: HIV Infections / metabolism Immunology and Allergy CCR10 Intestinal Mucosa MESH: T-Lymphocyte Subsets / metabolism biology MESH: Host-Pathogen Interactions / immunology hemic and immune systems MESH: Inflammation Mediators / metabolism 3. Good health Cell biology Chemotaxis Leukocyte Chemokines CC Host-Pathogen Interactions MESH: T-Lymphocyte Subsets / immunology Cytokines MESH: Chemotaxis Leukocyte / genetics [SDV.IMM]Life Sciences [q-bio]/Immunology MESH: Intestinal Mucosa / metabolism Antibody Inflammation Mediators MESH: Host-Pathogen Interactions / genetics MESH: Chemokines CC / metabolism Immunology MESH: HIV Infections / drug therapy MESH: Chemokine CCL20 / metabolism chemical and pharmacologic phenomena 03 medical and health sciences Humans MESH: HIV Infections / virology MESH: Intestinal Mucosa / immunology MESH: Chemotaxis Leukocyte / immunology Chemokine CCL20 MESH: Humans MESH: Cytokines / metabolism Chemotaxis CCL20 030104 developmental biology MESH: HIV-1 / immunology biology.protein HIV-1 MESH: Biomarkers CCL28 Ex vivo Biomarkers 030215 immunology MESH: HIV Infections / immunology |
Zdroj: | Mucosal Immunology Mucosal Immunology, 2020, 14 (1), pp.219-228. ⟨10.1038/s41385-020-0286-6⟩ Mucosal Immunology, Nature Pub. Group, 2021, 14 (1), pp.219-228. ⟨10.1038/s41385-020-0286-6⟩ |
ISSN: | 1933-0219 1935-3456 |
Popis: | International audience; Gut CD4+ T cells are incompletely restored in most HIV-1-infected individuals on antiretroviral therapy, notably Th17 cells, a key subset in mucosal homeostasis. By contrast, gut Th22 cells are usually restored at normal frequencies. Th22 cells display a CCR6+CCR10+ phenotype and could thus respond to CCL20- and CCL28-mediated chemotaxis, while Th17 cells, which express CCR6 but not CCR10, depend on CCL20. Herein, we found that CCL28 is normally expressed by duodenal enterocytes of treated HIV-1-infected individuals, while CCL20 expression is blunted. Ex vivo, we showed that Th22 cells contribute to the reduction of CCL20 production by enterocytes through an IL-22- and IL-18-dependent mechanism. Th22 cells preferentially migrate via CCL20- rather than CCL28-mediated chemotaxis when both chemokines are available in the microenvironment. However, when the CCL20/CCL28 ratio drops, as in treated HIV-1-infected individuals, Th22 cells can migrate via the CCR10-CCL28 axis, as an alternative to CCR6-CCL20. This could explain the better reconstitution of gut Th22 compared with Th17 cells on antiretroviral therapy. Lastly, we assessed the relationships between the frequencies of gut Th17 and Th22 cells and inflammatory markers related to microbial translocation, and showed that Th22 cells do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals. |
Databáze: | OpenAIRE |
Externí odkaz: |